We are transforming the process of antibody discovery to enable the targeting of complex membrane protein receptors such as GPCRs. By moving discovery from the bench to the digital world, we free our partners from the limitations of lab-intensive assays.

This is achieved by harnessing the creative power of digital directed evolution integrated with physics-based computations, to discover new antibodies targeting complex membrane receptors.

In this way we accelerate the drug discovery process – identifying promising new antibody candidates significantly faster, achieving higher hit rates, and reducing the risks associated with drug development.​

By tackling the most intractable diseases – from cancers to cardiovascular and neurological disorders – we bring life-changing therapies to patients and lasting value to our partners.